(Q30365502)

21 June 2017

1 reference

title

A history of AIDS: looking back to see ahead. (English)

1 reference

21 June 2017

Warner C Greene

1

1 reference

21 June 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

European Journal of Immunology

21 June 2017

published in

1 reference

21 June 2017

volume

37 Suppl 1

1 reference

21 June 2017

page(s)

S94-102

1 reference

Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Serological Analysis of a Subgroup of Human T-Lymphotropic Retroviruses (HTLV-III) Associated with AIDS

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Isolation of Lymphocytopathic Retroviruses from San Francisco Patients with AIDS

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Seroepidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Antibodies Reactive with Human T-Lymphotropic Retroviruses (HTLV-III) in the Serum of Patients with AIDS

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Complete nucleotide sequence of the AIDS virus, HTLV-III

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2).

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Nucleotide sequence of the AIDS virus, LAV

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Genomic diversity of human T-lymphotropic virus type III (HTLV-III).

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Identification of a major co-receptor for primary isolates of HIV-1

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

HIV-1 integration in the human genome favors active genes and local hotspots

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

A potent and orally active HIV-1 integrase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Importance of the nef gene for maintenance of high virus loads and for development of AIDS

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Slim disease: a new disease in Uganda and its association with HTLV-III infection.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

https://api.crossref.org/works/10.1002%2FEJI.200737441

1 reference

7 January 2021

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

The challenge of viral reservoirs in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Going wild: lessons from naturally occurring T-lymphotropic lentiviruses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Microbial translocation is a cause of systemic immune activation in chronic HIV infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Male circumcision to cut HIV risk in the general population.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

AIDS. Promote HIV chemoprophylaxis research, don't prevent it.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737441

7 January 2021

Identifiers

DOI

10.1002/EJI.200737441

1 reference

21 June 2017

1 reference